What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

JAK-STAT Signaling: Mechanism, Regulation, and Disease

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to JAK-STAT Signaling

The Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway is a highly conserved, rapid signaling cascade that transduces extracellular cytokine and growth factor signals into transcriptional responses in the nucleus. Unlike many signaling pathways that rely on second messengers or kinase cascades with multiple amplification steps, JAK-STAT signaling is remarkably direct: receptor-associated kinases phosphorylate latent transcription factors, which then translocate to the nucleus and alter gene expression. This simplicity enables cells to respond to cytokines within minutes, making the pathway essential for immune defense, hematopoiesis, and tissue homeostasis.

Historical context

The pathway emerged from two parallel lines of investigation in the early 1990s. Interferon (IFN) signaling had long served as a model for studying cytokine responses, but the molecular mechanism remained obscure. In 1989, researchers studying IFN-induced gene transcription identified a protein complex, termed ISGF3, that bound to interferon-stimulated response elements. The DNA-binding component of this complex was cloned and named STAT1. Concurrently, work on the IFN-α/β receptor identified two receptor-associated tyrosine kinases, later named JAK1 and TYK2, that were essential for signal transduction. The term "Janus kinase" derives from the two-faced Roman god Janus, reflecting the kinase's dual kinase-like domains—one catalytically active and one catalytically inactive but structurally important. The connection between JAKs and STATs was cemented when it was shown that JAK-mediated tyrosine phosphorylation of STAT1 was required for its nuclear translocation and DNA binding.

Core components: JAKs and STATs

The mammalian genome encodes four JAK family members: JAK1, JAK2, JAK3, and TYK2. These are large (~120–140 kDa) non-receptor tyrosine kinases composed of seven JAK homology (JH) domains. The C-terminal JH1 domain is the catalytically active kinase domain, while the adjacent JH2 domain is a pseudokinase domain that regulates JH1 activity. The N-terminal FERM (four-point-one, ezrin, radixin, moesin) domain mediates receptor binding. JAK1, JAK2, and TYK2 are broadly expressed, whereas JAK3 expression is restricted to hematopoietic cells.

The STAT family comprises seven members in mammals: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. These proteins share a conserved architecture: an N-terminal domain involved in dimerization, a coiled-coil domain, a DNA-binding domain, a Src homology 2 (SH2) domain that mediates recruitment to phosphotyrosine motifs and STAT dimerization, and a C-terminal transactivation domain. STATs exist as latent monomers in the cytoplasm and require tyrosine phosphorylation for activation. The specific combination of JAKs and STATs engaged by a given cytokine determines the transcriptional outcome, providing signal specificity within a shared framework.

The JAK-STAT Signaling Mechanism

The JAK-STAT cascade proceeds through a series of well-defined molecular events, from ligand binding at the cell surface to transcriptional regulation in the nucleus. Understanding each step is essential for interpreting experimental data and for appreciating how mutations at different points produce distinct disease phenotypes.

Ligand-receptor interaction

Cytokines bind to their cognate receptors, which are typically pre-associated with JAKs. Most cytokine receptors lack intrinsic kinase activity and instead rely on JAKs for signaling. Receptor engagement induces either homodimerization (e.g., erythropoietin receptor, growth hormone receptor) or heterodimerization (e.g., IFN-γ receptor composed of IFNGR1 and IFNGR2 subunits). This dimerization brings two JAKs into close proximity, allowing trans-phosphorylation of activating tyrosine residues within the JAK activation loop. For example, JAK2 activation requires phosphorylation of tyrosine residues Y1007 and Y1008 in its kinase domain. This phosphorylation induces a conformational change that increases catalytic activity by several orders of magnitude.

The activated JAKs then phosphorylate specific tyrosine residues on the receptor cytoplasmic tails. These phosphotyrosine motifs serve as docking sites for STAT proteins, which bind via their SH2 domains. The specificity of this interaction is determined by the amino acid sequence surrounding the phosphotyrosine. For instance, the IFN-γ receptor contains a STAT1-binding motif (YDKPH) that is specifically recognized by STAT1's SH2 domain, whereas the IL-6 receptor gp130 subunit contains YXXQ motifs that preferentially recruit STAT3.

JAK activation and STAT recruitment

Once recruited to the receptor, STATs themselves become substrates for JAK-mediated phosphorylation. The critical phosphorylation event occurs on a single conserved tyrosine residue near the C-terminus—for example, Y701 in STAT1, Y705 in STAT3, and Y694 in STAT5A. This phosphorylation is absolutely required for STAT activation; mutation of this residue to phenylalanine generates dominant-negative STAT proteins that cannot dimerize or translocate to the nucleus.

The kinetics of STAT phosphorylation are rapid. Within 1–5 minutes of cytokine stimulation, phospho-STAT levels peak, and the signal is typically extinguished within 30–60 minutes due to the action of negative regulators. This transient nature is critical for proper cellular responses, as sustained STAT activation is associated with oncogenic transformation.

STAT dimerization and nuclear import

Phosphorylated STATs dimerize through reciprocal SH2-phosphotyrosine interactions: the SH2 domain of one STAT monomer binds the phosphotyrosine of its partner. This creates a parallel dimer in which the DNA-binding domains are oriented to recognize palindromic response elements. STAT dimers then translocate to the nucleus. Although the precise mechanism of nuclear import remains incompletely defined, it involves the importin-α/β pathway. For STAT1, phosphorylation induces a conformational change that exposes a nuclear localization signal recognized by importin-α5. Nuclear export is mediated by CRM1 (chromosomal region maintenance 1), and the balance between import and export determines the nuclear accumulation of activated STATs.

In the nucleus, STAT dimers bind to specific DNA response elements. STAT1 and STAT3 recognize the gamma-activated sequence (GAS) motif, a palindromic sequence with the consensus TTCN₃GAA. STAT1/STAT2 heterodimers, in complex with IRF9, bind to interferon-stimulated response elements (ISREs) with the consensus AGTTTCNNTTTCNC. The transcriptional response is further modulated by recruitment of coactivators such as CBP/p300, which acetylate histones and promote chromatin remodeling.

Regulation of JAK-STAT Signaling

Given the potency of JAK-STAT signaling, multiple layers of negative regulation ensure that signals are appropriately terminated and that basal activity remains low. Dysregulation of these inhibitory mechanisms contributes to inflammatory diseases and cancer.

SOCS family

The suppressors of cytokine signaling (SOCS) proteins are the most well-characterized negative regulators of JAK-STAT signaling. The SOCS family comprises eight members (SOCS1–7 and CIS), each containing a central SH2 domain and a C-terminal SOCS box. SOCS proteins are induced by JAK-STAT signaling itself, creating a classic negative feedback loop. For example, IFN-γ stimulation induces SOCS1 expression, which then binds to JAK2 via its SH2 domain and inhibits kinase activity through its kinase inhibitory region (KIR). SOCS1 can also recruit the ubiquitin ligase machinery through its SOCS box, targeting JAKs for proteasomal degradation. SOCS3 similarly inhibits JAK2 but also binds to phosphorylated receptor motifs, competing with STATs for receptor docking sites. The kinetics of SOCS induction—typically detectable within 30–60 minutes of stimulation—explain the transient nature of STAT phosphorylation.

PIAS proteins

Protein inhibitors of activated STATs (PIAS) constitute a second family of negative regulators. Four PIAS proteins exist in mammals: PIAS1, PIAS3, PIASx, and PIASy. PIAS proteins bind directly to activated STAT dimers and inhibit their DNA-binding activity. PIAS1, for instance, binds to STAT1 and blocks its association with GAS elements. Additionally, PIAS proteins possess SUMO E3 ligase activity and can conjugate small ubiquitin-like modifier (SUMO) to STATs, which may alter their subcellular localization or stability. Unlike SOCS proteins, PIAS expression is largely constitutive, providing a baseline level of inhibition.

Phosphatases

Protein tyrosine phosphatases (PTPs) provide rapid, constitutive dephosphorylation of JAKs and STATs. The SH2 domain-containing phosphatase SHP1 (encoded by PTPN6) is expressed primarily in hematopoietic cells and dephosphorylates JAKs, terminating kinase activity. SHP2 (encoded by PTPN11) has broader expression and can both positively and negatively regulate signaling depending on context. The T-cell protein tyrosine phosphatase (TC-PTP, encoded by PTPN2) dephosphorylates STAT1 and STAT3 in the nucleus, promoting their export to the cytoplasm. The receptor-like phosphatase CD45 dephosphorylates JAKs in hematopoietic cells. The importance of these phosphatases is underscored by the phenotype of Ptpn2-deficient mice, which die within weeks of birth due to severe inflammation caused by uncontrolled STAT1 signaling.

Crosstalk with other signaling pathways

JAK-STAT signaling does not operate in isolation. Extensive crosstalk with other pathways modulates both the amplitude and duration of STAT activation. For example, the mitogen-activated protein kinase (MAPK) pathway can phosphorylate STATs on serine residues (e.g., S727 in STAT1 and STAT3), which enhances their transcriptional activity. The PI3K-AKT pathway can also influence STAT function through mTOR-mediated phosphorylation. Conversely, STAT3 can regulate the expression of genes involved in other signaling cascades, creating complex regulatory networks. The Nf Kappa B Signaling Pathway shares several target genes with JAK-STAT signaling, particularly those encoding inflammatory cytokines and chemokines, and the two pathways often cooperate in innate immune responses. Similarly, the Notch Signaling Pathway and Wnt Signaling Pathway can intersect with JAK-STAT at the level of transcriptional regulation in developmental contexts, though the molecular details of these interactions remain less well defined than the MAPK and PI3K crosstalk.

Physiological Roles of JAK-STAT Signaling

The JAK-STAT pathway mediates the effects of over 50 cytokines and growth factors, making it indispensable for a wide range of physiological processes. The specific outcomes depend on which JAKs and STATs are engaged and the cellular context.

Immune response

JAK-STAT signaling is central to both innate and adaptive immunity. Type I interferons (IFN-α/β) activate JAK1 and TYK2, leading to STAT1/STAT2 heterodimer formation and the induction of antiviral genes such as MX1, OAS1, and ISG15. IFN-γ activates JAK1 and JAK2, promoting STAT1 homodimerization and macrophage activation, including upregulation of MHC class II and inducible nitric oxide synthase. Interleukin-6 (IL-6) activates STAT3, which drives the acute-phase response and promotes T-helper 17 (Th17) cell differentiation. IL-12 activates STAT4, which is essential for Th1 differentiation, while IL-4 activates STAT6 to promote Th2 responses. The specificity of these responses is remarkable: STAT4 and STAT6 are activated by distinct cytokines and produce opposing T-cell fates, yet both use the same core JAK-STAT machinery.

Hematopoiesis

Erythropoietin (EPO) signaling through JAK2 and STAT5 is essential for red blood cell production. EPO binding to its receptor activates JAK2, which phosphorylates STAT5, leading to expression of anti-apoptotic genes such as BCL-XL that support erythroid progenitor survival. Thrombopoietin similarly signals through JAK2/STAT5 to drive megakaryocyte differentiation and platelet production. The critical role of JAK2 in hematopoiesis is demonstrated by the embryonic lethality of Jak2-null mice, which die around embryonic day 12.5 due to failure of definitive erythropoiesis. STAT5A/STAT5B double-knockout mice also exhibit severe anemia and impaired erythropoiesis, confirming the non-redundant role of STAT5 in this process.

Growth and development

Growth hormone (GH) signals through JAK2 and STAT5 to regulate postnatal growth. GH binding to its receptor activates JAK2, leading to STAT5 phosphorylation and induction of insulin-like growth factor 1 (IGF-1) expression in the liver. Mutations in the GH receptor or JAK2 that impair STAT5 activation cause growth retardation. Prolactin, which signals through JAK2/STAT5, is required for mammary gland development and lactation. In the nervous system, JAK-STAT signaling contributes to astrocyte differentiation and neuroprotection, though the specific cytokines involved are less well characterized than in the immune system. The pathway also plays roles in embryonic development, as evidenced by the requirement for STAT3 in gastrulation—Stat3-null mice die during early embryogenesis.

JAK-STAT in Disease

Given the pathway's broad physiological roles, it is unsurprising that dysregulated JAK-STAT signaling underlies numerous human diseases. Both gain-of-function and loss-of-function mutations have been identified, producing distinct clinical phenotypes.

Oncogenic JAK/STAT mutations

Constitutive activation of JAK-STAT signaling is a common feature of many cancers. The most well-characterized mutation is JAK2 V617F, a valine-to-phenylalanine substitution at position 617 in the JH2 pseudokinase domain. This mutation, found in approximately 95% of patients with polycythemia vera and about 50% of those with essential thrombocythemia and primary myelofibrosis, disrupts the autoinhibitory function of the pseudokinase domain, resulting in constitutive JAK2 kinase activity. The activated JAK2 phosphorylates STAT5, driving cytokine-independent proliferation of hematopoietic progenitors.

In addition to JAK2 mutations, activating mutations in STAT genes have been identified. STAT3 mutations, particularly in the SH2 domain, occur in large granular lymphocytic leukemia and cause constitutive STAT3 dimerization and transcriptional activity. STAT5B mutations with similar gain-of-function effects have been found in NK/T-cell lymphomas. Chromosomal translocations that fuse JAK2 to the TEL (ETV6) gene create constitutively active fusion proteins in certain leukemias. Beyond direct mutations, aberrant upstream signaling—such as autocrine IL-6 production in multiple myeloma—can drive persistent STAT3 activation, contributing to tumor cell survival and proliferation.

Inflammatory diseases

Chronic activation of JAK-STAT signaling contributes to inflammatory and autoimmune diseases. In rheumatoid arthritis, IL-6 signaling through STAT3 promotes synovial inflammation and joint destruction. Inflammatory bowel disease is associated with excessive STAT3 activation in intestinal epithelial cells and immune cells. Psoriasis involves dysregulated IL-23/STAT3 signaling in T cells. The central role of JAK-STAT in these conditions has made JAK inhibitors attractive therapeutic agents, as discussed below. Gain-of-function mutations in STAT1 cause chronic mucocutaneous candidiasis, an immunodeficiency characterized by persistent fungal infections, due to enhanced IFN-γ signaling that skews T-cell differentiation away from Th17 responses.

Primary immunodeficiencies

Loss-of-function mutations in JAKs and STATs cause primary immunodeficiencies with characteristic clinical presentations. JAK3 mutations cause severe combined immunodeficiency (SCID), characterized by absence of T cells and NK cells with normal B-cell numbers (T⁻B⁺NK⁻ SCID). This phenotype reflects JAK3's essential role in signaling through the common gamma chain (γc), which is shared by receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Mutations in STAT1 cause Mendelian susceptibility to mycobacterial disease, as STAT1 is required for IFN-γ-mediated macrophage activation. STAT5B mutations cause growth hormone insensitivity with immunodeficiency, reflecting STAT5B's dual roles in growth and immune function. These genetic disorders highlight the non-redundant functions of individual JAK and STAT family members.

Therapeutic Targeting of JAK-STAT

The central role of JAK-STAT signaling in disease has driven intensive drug development efforts, particularly targeting the JAK kinases with small-molecule inhibitors.

JAK inhibitors in the clinic

Several JAK inhibitors have received regulatory approval for clinical use. Ruxolitinib, a JAK1/JAK2 inhibitor, was the first approved JAK inhibitor and is used to treat myelofibrosis and polycythemia vera. By inhibiting constitutively active JAK2, ruxolitinib reduces splenomegaly and constitutional symptoms in myelofibrosis patients. Tofacitinib, a JAK1/JAK3 inhibitor, is approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Baricitinib, a JAK1/JAK2 inhibitor, is used for rheumatoid arthritis. Upadacitinib, a selective JAK1 inhibitor, has been approved for rheumatoid arthritis and atopic dermatitis. These agents are administered orally, a significant advantage over biologic therapies that require injection.

The clinical success of JAK inhibitors stems from their ability to block multiple cytokine pathways simultaneously. For example, in rheumatoid arthritis, tofacitinib inhibits signaling through the γc cytokines (IL-2, IL-15, IL-21) via JAK3, as well as IL-6 signaling via JAK1, thereby suppressing multiple pro-inflammatory pathways. However, this broad inhibition also underlies the major adverse effects, including increased risk of infections (particularly herpes zoster), anemia, and dyslipidemia.

Challenges and future directions

Current JAK inhibitors are relatively non-selective, inhibiting multiple JAK family members. This broad activity contributes to both efficacy and toxicity. The development of more selective inhibitors—such as selective JAK1 or JAK3 inhibitors—aims to improve the therapeutic window. However, the functional redundancy among JAKs complicates this approach; for example, JAK1 and JAK2 both contribute to IL-6 signaling, so selective JAK1 inhibition may not fully suppress this pathway.

An alternative strategy is to target STAT proteins directly. STAT3, in particular, is an attractive target given its role in multiple cancers and inflammatory diseases. However, developing small-molecule inhibitors of STAT3 has proven challenging because STAT3 lacks a well-defined enzymatic active site. Approaches under investigation include phosphopeptide mimetics that block STAT3 SH2 domain interactions, decoy oligonucleotides that compete for STAT3 DNA binding, and antisense oligonucleotides that reduce STAT3 expression. These strategies remain experimental, and no STAT-targeted therapy has yet received regulatory approval.

Methods to Study JAK-STAT Signaling

Understanding the experimental approaches used to study JAK-STAT signaling is essential for interpreting the primary literature and for designing experiments.

Western blotting

Western blotting for phospho-STAT proteins is the most common method to assess pathway activation. Cells are stimulated with the cytokine of interest, lysed in buffer containing protease and phosphatase inhibitors (typically 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 1 mM Na₃VO₄, 1 mM NaF), and proteins are separated by SDS-PAGE. After transfer to a membrane, phospho-specific antibodies—for example, anti-phospho-STAT3 (Y705)—are used to detect activated STATs. The membrane is then stripped and re-probed with an antibody against total STAT3 to control for loading. A time-course experiment (0, 5, 15, 30, 60 minutes post-stimulation) reveals the kinetics of activation and deactivation. It is critical to include unstimulated controls, as some cell lines exhibit constitutive STAT phosphorylation.

Luciferase reporter assays

Reporter assays measure JAK-STAT transcriptional activity. A plasmid containing a STAT-responsive promoter (e.g., the GAS element from the IRF1 gene for STAT1, or the SIE element for STAT3) upstream of the firefly luciferase gene is transfected into cells. After cytokine stimulation, luciferase activity is measured using a luminometer and normalized to a co-transfected Renilla luciferase control. This assay is quantitative and can be used to test the effects of inhibitors, dominant-negative constructs, or mutations in pathway components.

Genetic models

Knockout mice have been instrumental in defining the physiological roles of JAKs and STATs. As noted, Jak2-null and Stat3-null mice are embryonic lethal, necessitating conditional knockout approaches using Cre-lox technology. For example, conditional deletion of STAT3 in macrophages using LysM-Cre mice has revealed its role in inflammatory responses. Cell lines with targeted gene disruption, such as JAK-deficient γ2A fibrosarcoma cells, have been used to define the specific JAK requirements for different cytokines. More recently, CRISPR-Cas9 genome editing has enabled rapid generation of knockout cell lines for functional studies.

Chromatin immunoprecipitation

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) identifies genome-wide STAT binding sites. Cells are cross-linked with 1% formaldehyde for 10 minutes at room temperature, and chromatin is sheared by sonication to fragments of approximately 200–500 base pairs. STAT-specific antibodies are used to immunoprecipitate STAT-DNA complexes, and the associated DNA is purified and sequenced. This approach has revealed that STATs bind thousands of genomic loci, many of which are in enhancer regions rather than promoters. ChIP-seq data can be integrated with gene expression data (RNA-seq) to identify direct STAT target genes.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual difficulties when learning about JAK-STAT signaling. Recognizing these pitfalls will improve understanding and exam performance.

Distinguishing JAKs and STATs

A common error is confusing the roles of JAKs and STATs. JAKs are tyrosine kinases that phosphorylate STATs; they do not bind DNA or directly regulate transcription. STATs are latent transcription factors that require JAK-mediated phosphorylation for activation; they do not possess kinase activity. This division of labor is fundamental: JAKs are the enzymes, STATs are the substrates and effectors. Another frequent confusion involves the number of JAKs and STATs—there are four JAKs and seven STATs in mammals, and the specific combination engaged depends on the cytokine and receptor.

Feedback loops

Students often overlook the negative feedback regulation that terminates JAK-STAT signaling. The pathway is not constitutively active; rather, it is tightly controlled by SOCS proteins, PIAS proteins, and phosphatases. A typical exam question might ask why STAT phosphorylation is transient despite continuous cytokine stimulation. The answer involves SOCS-mediated inhibition of JAK activity and receptor dephosphorylation. Understanding that SOCS genes are themselves STAT targets is crucial—this creates a negative feedback loop where pathway activation induces its own inhibitors.

Interpreting phospho-blots

Misinterpreting Western blot data is another common pitfall. A phospho-STAT band does not necessarily indicate transcriptional activity—it only indicates phosphorylation. Some phosphorylation events (e.g., serine phosphorylation) can occur without full transcriptional activation. Conversely, the absence of detectable phospho-STAT does not always mean the pathway is inactive, as dephosphorylation may occur rapidly during sample preparation. It is also important to distinguish between tyrosine phosphorylation (required for dimerization and nuclear translocation) and serine phosphorylation (which modulates but is not required for activity). When analyzing blots, always check that total STAT levels are equal between samples; differences in loading can produce artifactual differences in phospho-STAT signals.

Summary and Key Takeaways

The JAK-STAT pathway is a paradigm of direct signal transduction, linking cytokine receptor engagement to transcriptional responses without intermediate second messengers. Its components are few, its kinetics are rapid, and its regulation is multilayered. Understanding this pathway provides insight into fundamental principles of cell signaling, including receptor dimerization, kinase-substrate specificity, negative feedback, and the molecular basis of disease.

Frequently Asked Questions

What is the JAK-STAT signaling pathway?

The JAK-STAT signaling pathway is a cellular signaling cascade that transmits information from cytokines and growth factors at the cell surface to the nucleus, where it regulates gene expression. It involves receptor-associated JAK tyrosine kinases that phosphorylate STAT transcription factors, which then dimerize, translocate to the nucleus, and bind DNA to modulate transcription.

How does JAK-STAT signaling work?

Cytokine binding induces receptor dimerization, bringing JAKs into proximity for trans-phosphorylation and activation. Activated JAKs phosphorylate tyrosine residues on the receptor, creating docking sites for STAT proteins. Receptor-bound STATs are then phosphorylated by JAKs, causing STAT dimerization via SH2-phosphotyrosine interactions. STAT dimers translocate to the nucleus, bind specific DNA response elements, and regulate target gene expression.

What are JAKs and STATs?

JAKs (Janus kinases) are non-receptor tyrosine kinases that associate with cytokine receptors. There are four family members: JAK1, JAK2, JAK3, and TYK2. STATs (signal transducers and activators of transcription) are latent cytoplasmic transcription factors that are activated by JAK-mediated phosphorylation. There are seven family members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.

What is the role of SOCS in JAK-STAT signaling?

SOCS (suppressors of cytokine signaling) proteins are negative feedback regulators induced by JAK-STAT signaling. They inhibit the pathway by binding to JAKs and inhibiting their kinase activity, competing with STATs for receptor docking sites, and targeting signaling components for proteasomal degradation.

What diseases are associated with JAK-STAT mutations?

Activating mutations cause myeloproliferative neoplasms (JAK2 V617F), leukemias (STAT3, STAT5B mutations), and inflammatory diseases. Loss-of-function mutations cause immunodeficiencies, including JAK3-deficient SCID, STAT1 deficiency causing susceptibility to mycobacterial disease, and STAT5B deficiency causing growth hormone insensitivity with immunodeficiency.

How is JAK-STAT signaling studied experimentally?

Common methods include Western blotting with phospho-specific antibodies to detect STAT activation, luciferase reporter assays to measure transcriptional activity, knockout or knockdown models to assess gene function, and ChIP-seq to identify genome-wide STAT binding sites.

What are JAK inhibitors?

JAK inhibitors are small-molecule drugs that block JAK kinase activity. Examples include ruxolitinib (JAK1/JAK2 inhibitor for myelofibrosis), tofacitinib (JAK1/JAK3 inhibitor for rheumatoid arthritis), and baricitinib (JAK1/JAK2 inhibitor for rheumatoid arthritis). They work by preventing STAT phosphorylation and downstream gene expression.

Key Takeaways

JAK-STAT signaling is a direct, rapid pathway from cytokine receptor to gene transcription, involving only a few core components.
Four JAKs and seven STATs provide combinatorial specificity for over 50 cytokines and growth factors.
The pathway is tightly regulated by SOCS proteins (negative feedback), PIAS proteins, and protein tyrosine phosphatases.
JAK-STAT signaling is essential for immunity, hematopoiesis, growth, and development, as demonstrated by knockout phenotypes.
Dysregulated JAK-STAT signaling causes cancers (JAK2 V617F), inflammatory diseases, and primary immunodeficiencies.
JAK inhibitors are clinically approved for myelofibrosis, rheumatoid arthritis, and other conditions; STAT-targeted therapies remain experimental.
Key experimental methods include phospho-specific Western blotting, luciferase reporters, genetic models, and ChIP-seq.